share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Director MOTT DAVID M

Novavax | 4: Statement of changes in beneficial ownership of securities-Director MOTT DAVID M

諾瓦瓦克斯醫藥 | 4:持股變動聲明-董事 MOTT DAVID M
美股sec公告 ·  06/14 16:29
Moomoo AI 已提取核心訊息
David M. Mott, reported a completed transaction involving the acquisition of 6,670 shares of Novavax Inc (NVAX) common stock on June 12, 2024. The shares were acquired at a price of $0.00, indicating the transaction was likely an exercise or conversion of derivative securities. Following this transaction, Mott's direct holdings in Novavax increased to a total of 50,470 shares. The nature of the transaction suggests an investment in the company's growth and potential, as Mott increases his stake in the pharmaceutical firm.
David M. Mott, reported a completed transaction involving the acquisition of 6,670 shares of Novavax Inc (NVAX) common stock on June 12, 2024. The shares were acquired at a price of $0.00, indicating the transaction was likely an exercise or conversion of derivative securities. Following this transaction, Mott's direct holdings in Novavax increased to a total of 50,470 shares. The nature of the transaction suggests an investment in the company's growth and potential, as Mott increases his stake in the pharmaceutical firm.
David M·莫特於2024年6月12日報告完成了一筆交易,收購了諾瓦瓦克斯醫藥(NVAX)的6,670股普通股。這些股票的購買價格爲0.00美元,表明該交易很可能是衍生證券的行權或轉換。在此交易之後,莫特在諾瓦瓦克斯醫藥的直接持股增加至總共50,470股。交易的性質表明莫特對該藥品公司的增長和潛力表示投資,因爲他增加了他在該製藥公司的持股比例。
David M·莫特於2024年6月12日報告完成了一筆交易,收購了諾瓦瓦克斯醫藥(NVAX)的6,670股普通股。這些股票的購買價格爲0.00美元,表明該交易很可能是衍生證券的行權或轉換。在此交易之後,莫特在諾瓦瓦克斯醫藥的直接持股增加至總共50,470股。交易的性質表明莫特對該藥品公司的增長和潛力表示投資,因爲他增加了他在該製藥公司的持股比例。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息